GET DAILY SIGNALSCuprina Holdings (CUPR) Holds Near $1.80 After -74% Annual Decline
Key Takeaways
- Cuprina Holdings (Cayman) Limited is a Singapore-based micro-cap biomedical company focused on chronic wound care, listed on Nasdaq under the ticker CUPR.
- The stock has traded in a volatile range over the trailing 30 days, ending near $1.80 for a modest single-digit percentage decline that keeps the move below a sharp-swing threshold.
- Shares remain far below their 52-week high of $14.80, reflecting a decline of roughly 74% over the past year.
- The company's flagship product, MEDIFLY, is a medical-grade sterile blowfly-larvae bio-dressing used for biological debridement of chronic wounds, with FDA 510(k) clearance serving as a key regulatory milestone.
- Cuprina operates at an early commercial stage, with about $38.8K in trailing revenue and a net loss near $3.6 million, underscoring its pre-scale, high-risk profile.
- Its next scheduled earnings release is set for late November 2026.
- For deeper detail on valuation and expectations, review this ticker's Price Targets, Earnings, and Forecast pages on Tickeron.
Where CUPR Stands in the Market Right Now
CUPR ended its most recent session near $1.80, leaving the company with a market capitalization of roughly $12.6 million and about 7.0 million shares outstanding. The name carries the hallmarks of a thinly traded micro-cap: average 20-day volume sits around 124,000 shares, and daily activity can swing sharply from session to session. The 52-week range illustrates the scale of the drawdown, with shares trading between a low of $1.45 and a high of $14.80. Technical positioning reflects that pressure, with the stock holding below its 50-day moving average near $2.19 and its 200-day moving average near $2.97, while its relative strength index hovers near the low-40s. Over the trailing 30 days, CUPR moved from roughly $1.90–$2.00 in early October to about $1.80 in early November, a single-digit percentage pullback that remains within a broader consolidation rather than a decisive trend.
Understanding Cuprina's Focus on Wound Care
Founded in 2019 and based in Singapore, Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company focused on developing and commercializing products for chronic wound management. Its core offering, MEDIFLY, is a line of medical-grade sterile blowfly-larvae bio-dressing products that serve as a biological debridement tool for chronic wounds. The company is also developing collagen-based dressings, including sponges, particles, and hydrogels derived from bullfrog collagen obtained through the valorization of abattoir waste streams, as well as products using medical leeches for wound treatment.
The company's competitive positioning centers on a niche within the wound-care segment: biological debridement, which aims to remove non-viable tissue from non-healing wounds. Cuprina is pursuing FDA 510(k) clearance for its MEDIFLY products, a regulatory pathway that, if successful, would expand its addressable market into the United States. As a subsidiary of Cuprina Holding Pte. Ltd., the company completed its Nasdaq listing in April 2025. Investors follow the stock primarily for its regulatory catalysts and potential commercialization progress, given its early-stage financial profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What's Moving the Needle for CUPR Lately
CUPR's recent trading has been characterized by sharp volatility rather than a single dominant catalyst. After a steep decline that took shares to a 52-week low of $1.45 in mid-September, the stock rebounded toward the $2.00–$2.30 area before pulling back again into the $1.80 range. This whipsaw pattern is consistent with a thinly traded micro-cap where modest order flow can produce outsized percentage moves.
On the fundamental side, the company's most significant forward-looking milestone remains the pursuit of FDA 510(k) clearance for MEDIFLY. Regulatory developments of this kind typically carry outsized weight for early-stage medical-device and biotechnology issuers, and any updates on the application's progress would be closely watched. The company's financial position also shapes sentiment: with roughly $38.8K in trailing twelve-month revenue and a net loss near $3.6 million, Cuprina remains dependent on successful regulatory outcomes, commercialization execution, and continued access to capital. The next scheduled earnings report, expected in late November 2026, will provide an updated view of its balance sheet and operating momentum.
What to Watch in the Year Ahead
Looking ahead, the most consequential variable for CUPR is regulatory: progress toward FDA 510(k) clearance for MEDIFLY would materially reshape the company's growth narrative and addressable market. Investors should also monitor the commercialization ramp and any initial traction in existing markets, alongside the company's cash position and financing needs given its ongoing operating losses. Macroeconomic conditions, including the cost and availability of capital for micro-cap issuers, remain a relevant backdrop. Competitive dynamics within the chronic wound-care and biological debridement space will also matter as larger, better-capitalized players operate in adjacent segments. Finally, quarterly earnings and any updates to guidance or development timelines will help clarify whether the company is converting its regulatory ambitions into measurable progress. None of these factors constitute a forecast, and the stock's volatility warrants careful attention to position sizing and risk.
Integrating AI Insights into My Analysis
In my research process, I often turn to Tickeron's Trending AI Robots page. It brings together a curated selection of top-performing AI-driven trading bots spanning various approaches and timeframes. This gives me a focused view of automated strategies that stand out, which can be particularly helpful when monitoring volatile micro-caps like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for CUPR turns negative, indicating new downward trend
CUPR saw its Momentum Indicator move below the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator turned negative. In 24 of the 26 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CUPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 17 of 20 cases where CUPR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where CUPR advanced for three days, in 58 of 67 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.454) is normal, around the industry mean (4.964). P/E Ratio (-0.986) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (104.167) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. CUPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CUPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement